Drug Development Services
Bringing new drugs to the clinic faster
World-class integrated preclinical research and testing services
Hoeford Research has joined forces with Medicilon - a global, publicly-listed preclinical CRO with laboratories in Shanghai, China and Boston, US - to help biotechnology and pharmaceutical start-ups face their financial, scientific, and physical resource constraints, and to meet the demand from drug developers and their investors for an outsourced regulatory testing partner that can deliver on time, within budget, and meet the demanding standards of scientific rigour and excellence at every stage.
To help you get your product to the clinic faster we offer an integrated preclinical R&D platform encompassing Drug Candidate Development and Pre-IND Safety and Efficacy Testing.
Drug Candidate Development
With new compounds, evaluation of the potential risks and hazards associated with potential drug candidates happens at a crucial time.
Investors are considering ongoing financial support in anticipation of significant return, while developers are calculating the likelihood of scientific success based on their understanding of complex data and regulatory requirements.
Early collaboration with a laboratory partner experienced in supporting organisations with limited resources helps to avoid the common mistakes developers make with their investors when communicating, presenting and interpreting testing data.
In collaboration with Medicilon, Hoeford Research provides managed access to expertise and testing facilities on three continents to meet your candidate development needs for non-GLP studies across hit identification, synthesis, lead optimisation and candidate selection.
Pre-IND Safety and Efficacy Testing
The transition from drug candidate to Investigational New Drug (IND) submission is also a significant milestone for investors because it instills confidence in the drug programme's viability as well as enhancing the likelihood of bringing the drug to market and delivering commercial success.
At this stage in the journey the emphasis on robust and comprehensive Pre-IND safety and efficacy testing becomes paramount, and choosing the right testing partner emerges as a cornerstone in the process.
The synergy between developer and testing partner enables seamless integration of different testing types within a consolidated platform. This can propel the drug's development journey by streamlining and optimising the regulatory testing process, ensuring compliance while significantly influencing cost management and shortening the time to market - a critical competitive advantage.
In collaboration with Medicilon, Hoeford Research co-creates and manages integrated GLP safety and efficacy study design and testing that is carefully sequenced around key scientific and business milestones, and carried out by 3,100 scientists and service personnel and combined laboratory space of over 90,000 square metres across three continents and time zones.